More Diagnostics, Inc. Signs an Agreement with Emery Pharma

Wednesday, April 11, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LOS OSOS, Calif., April 11, 2018 /PRNewswire/ -- More Diagnostics, Inc., an employee owned developer and manufacturer

of clinical diagnostic controls and Emery Pharma, a full-service contract research & development organization, specializing in microbiology, cell biology medicinal chemistry and bioanalytical services, announced the signing of a four-year agreement
with Emery Pharma to provide Liquid Chromatography Mass Spectrometry (LC-MS) services to More Diagnostics. The agreement covers the analysis of the full range of analytes available in the controls for immunoassays used for testing immunosuppressant drugs, such as Everolimus, Tacrolimus, Cyclosporine and Sirolimus (Rapamycin).

"We are very pleased to team with Emery Pharma as our partner in maintaining the highest level of quality and integrity of our products and collaborate with us the on-going development of new products," commented Endre Vargha, CEO of More Diagnostics.

About More Diagnostics

Founded in 1993, More Diagnostics is the leader in providing immunosuppressant assay controls to diagnostic equipment OEMs, hospitals and laboratories with worldwide distribution channels. Keeping with More's commitment for delivering reliable quality controls, the company has developed a stable liquid whole-blood Cyclosporine control that became the standard for the industry. Located on the Central Coast of California, the Company is fully certified; FDA and CMDCAS licensed, ISO 14385 certified including the CE Mark.

About Emery Pharma

Emery Pharma is an FDA registered, DEA licensed and cGMP/GLP compliant contract research & development organization focused on supporting mid-size biotech, pharma, synthetic fuel, agro chemistry, and novel battery technology. Located in Alameda, CA, Emery Pharma's experienced chemists and biologists, utilize modern, qualified equipment for a large variety of studies, including NMR, LCMS, Prep-HPLC, ICPMS, stability, dissolution, litigation support, expert witness and consulting services. The team also has significant experience and capabilities in medical chemistry, biological screening, and formulation development.  

Contact More Diagnostics at +1-800-758-0978 or send a message via its website https://www.morediagnostics.com/contact-us/

Contact Emery Pharma at +1-888-983-6379 or send a message through its website https://emerypharma.com/contact/

For More Diagnostics Media RelationsContact Jasmine Moore at +1-805-528-6005jmoore@morediagnostics.comConnect with us on LinkedIn

 

Cision View original content:http://www.prnewswire.com/news-releases/more-diagnostics-inc-signs-an-agreement-with-emery-pharma-300628194.html

SOURCE More Diagnostics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store